Head to Head Survey: Integra Lifesciences (IART) and T2 Biosystems (TTOO)

Integra Lifesciences (NASDAQ: IART) and T2 Biosystems (NASDAQ:TTOO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Earnings and Valuation

This table compares Integra Lifesciences and T2 Biosystems’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Integra Lifesciences $992.08 million 3.94 $74.56 million $0.61 81.70
T2 Biosystems $4.10 million 43.61 -$54.80 million ($1.90) -2.63

Integra Lifesciences has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Integra Lifesciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

87.6% of Integra Lifesciences shares are owned by institutional investors. Comparatively, 59.7% of T2 Biosystems shares are owned by institutional investors. 21.5% of Integra Lifesciences shares are owned by insiders. Comparatively, 38.7% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Integra Lifesciences and T2 Biosystems, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra Lifesciences 0 7 3 0 2.30
T2 Biosystems 1 1 4 0 2.50

Integra Lifesciences presently has a consensus target price of $51.88, suggesting a potential upside of 4.08%. T2 Biosystems has a consensus target price of $6.83, suggesting a potential upside of 36.94%. Given T2 Biosystems’ stronger consensus rating and higher probable upside, analysts plainly believe T2 Biosystems is more favorable than Integra Lifesciences.

Profitability

This table compares Integra Lifesciences and T2 Biosystems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra Lifesciences 4.52% 16.35% 6.83%
T2 Biosystems -1,497.70% -244.82% -78.53%

Volatility and Risk

Integra Lifesciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Summary

Integra Lifesciences beats T2 Biosystems on 8 of the 14 factors compared between the two stocks.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

About T2 Biosystems

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit